NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, February, 18th. The medical device company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.01. The medical device company earned $44.77 million during the quarter, compared to analysts' expectations of $60.60 million. AtriCure had a negative return on equity of 16.26% and a negative net margin of 15.25%. AtriCure's revenue for the quarter was down 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.21) earnings per share. View AtriCure's Earnings History.

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for AtriCure.

AtriCure issued an update on its FY20 earnings guidance on Tuesday, February, 18th. The company provided EPS guidance of -$1.24 to -$1.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($1.09). The company issued revenue guidance of $254 million to $261 million, compared to the consensus revenue estimate of $258.63 million.

7 brokers have issued 1-year price targets for AtriCure's stock. Their forecasts range from $30.00 to $52.00. On average, they anticipate AtriCure's stock price to reach $44.00 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for AtriCure.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

News coverage about ATRC stock has been trending positive on Friday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AtriCure earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for AtriCure.

AtriCure saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 873,400 shares, an increase of 11.7% from the January 15th total of 781,900 shares. Based on an average daily trading volume, of 234,200 shares, the short-interest ratio is currently 3.7 days. Approximately 2.3% of the shares of the stock are short sold. View AtriCure's Current Options Chain.

Some companies that are related to AtriCure include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), bluebird bio (BLUE), Cellectis (CLLS), Galectin Therapeutics (GALT), Neurocrine Biosciences (NBIX), Abbott Laboratories (ABT) and Allergan (AGN).

AtriCure's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.99%), Champlain Investment Partners LLC (3.16%), GW&K Investment Management LLC (2.96%), State Street Corp (2.49%), Tamarack Advisers LP (2.17%) and Peregrine Capital Management LLC (1.93%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Prudential Financial Inc., Man Group plc, SG Americas Securities LLC, Martingale Asset Management L P, Peregrine Capital Management LLC, Bessemer Group Inc. and Oxford Asset Management LLP. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar and Michael H Carrel. View Insider Buying and Selling for AtriCure.

ATRC stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Bridger Management LLC, GW&K Investment Management LLC, Point72 Asset Management L.P., Renaissance Technologies LLC, Landscape Capital Management L.L.C., BNP PARIBAS ASSET MANAGEMENT Holding S.A. and Sectoral Asset Management Inc. View Insider Buying and Selling for AtriCure.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRC stock can currently be purchased for approximately $38.42.

AtriCure has a market capitalization of $1.54 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

The official website for AtriCure is http://www.atricure.com/.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.